Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

541 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Late recurrence of small-cell lung cancer: treatment and outcome.
Sekine I, Nishiwaki Y, Kakinuma R, Kubota K, Hojo F, Matsumoto T, Ohmatsu H, Yokozaki M, Goto K, Kodama T. Sekine I, et al. Among authors: nishiwaki y. Oncology. 1996 Jul-Aug;53(4):318-21. doi: 10.1159/000227580. Oncology. 1996. PMID: 8692537
Second-line chemotherapy for relapsed small cell lung cancer.
Ebi N, Kubota K, Nishiwaki Y, Hojo F, Matsumoto T, Kakinuma R, Ohmatsu H, Sekine I, Yokosaki M, Gotoh K, Yamamoto H, Kodama T. Ebi N, et al. Among authors: nishiwaki y. Jpn J Clin Oncol. 1997 Jun;27(3):166-9. doi: 10.1093/jjco/27.3.166. Jpn J Clin Oncol. 1997. PMID: 9255271 Clinical Trial.
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
Ando M, Eguchi K, Shinkai T, Tamura T, Ohe Y, Yamamoto N, Kurata T, Kasai T, Ohmatsu H, Kubota K, Sekine I, Hojo N, Matsumoto T, Kodama T, Kakinuma R, Nishiwaki Y, Saijo N. Ando M, et al. Among authors: nishiwaki y. Br J Cancer. 1997;76(11):1494-9. doi: 10.1038/bjc.1997.584. Br J Cancer. 1997. PMID: 9400948 Free PMC article. Clinical Trial.
Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N. Furuse K, et al. Among authors: nishiwaki y. J Clin Oncol. 1998 Jun;16(6):2126-32. doi: 10.1200/JCO.1998.16.6.2126. J Clin Oncol. 1998. PMID: 9626212 Clinical Trial.
541 results